Semaglutide Synthesis: How the Molecule Behind Wegovy Is Made

What is semaglutide, and why does it need to be synthesised at all?

Your gut already makes a hormone called GLP-1. It is released after meals and signals the brain to reduce appetite, tells the pancreas to release insulin, and slows how quickly the stomach empties. Useful. The catch is that natural GLP-1 has a half-life of around two minutes; an enzyme called dipeptidyl peptidase-4 (DPP-4) destroys it almost immediately. That makes the natural version useless as a medicine on its own.

Semaglutide is a purpose-built version of GLP-1, engineered to activate the same receptor but resist destruction. It shares roughly 94 per cent of GLP-1's amino-acid sequence. The differences are deliberate: a single amino-acid swap near the N-terminus blocks DPP-4 from attacking the molecule, and a long fatty-acid chain is attached at a specific lysine residue. That fatty-acid chain is the key to the medicine's weekly dosing schedule. You can read a plain-language overview of how the drug behaves in the body on the semaglutide overview page.

A common misconception is that GLP-1 medicines are somehow extracted from natural sources, the way early insulin came from pig pancreases. They are not. Semaglutide is built entirely from scratch in a laboratory, amino acid by amino acid, using a method called solid-phase peptide synthesis.

How does solid-phase peptide synthesis actually build the molecule?

Solid-phase peptide synthesis (SPPS) is the industrial workhorse of modern peptide drug manufacturing. The process anchors a growing peptide chain to a solid resin bead, then adds one protected amino acid at a time in a carefully sequenced series of chemical reactions. Each coupling step is checked, excess reagents are washed away, and the protective groups on each amino acid are removed before the next one is added.

For semaglutide, the chain runs to 34 amino acids. Once the full sequence is assembled and cleaved from the resin, the raw peptide is purified by high-performance liquid chromatography to remove any incomplete sequences or side products. Manufacturing at pharmaceutical scale demands extraordinary purity; impurity profiles for injectable medicines are tightly regulated by the MHRA.

After purification, the fatty-acid side chain — a C18 diacid connected to the peptide by a linker — is attached at the lysine position. This is what gives semaglutide its albumin-binding property. Albumin is the most abundant protein in plasma; by hitching to it loosely and reversibly, semaglutide stays in circulation rather than being filtered out by the kidneys. The net effect is a half-life of approximately seven days, which is why once-weekly dosing is possible. The NHS semaglutide medicines page covers what this means in practical terms for patients.

Why does the oral form need different chemistry?

Injected semaglutide bypasses the gut entirely, so the fatty-acid trick is sufficient. Oral semaglutide faces a harder problem: the stomach is an acid bath, and peptides are digested by proteases in the small intestine. The oral form would be destroyed before it could do anything useful.

The solution is co-formulation with a small molecule called sodium N-(8-[2-hydroxylbenzoyl]amino)caprylate, known as SNAC. SNAC acts as an absorption enhancer. In the stomach, it buffers the local pH around the tablet as it dissolves, protecting the peptide from acid degradation. It also increases the permeability of the gastric mucosa at the absorption site, allowing semaglutide to cross into the bloodstream before it reaches the small intestine and its proteases.

This is why the tablet must be taken first thing in the morning on an empty stomach with a small amount of plain water and why food, coffee or other oral medicines must wait at least 30 minutes. Anything that dilutes or disrupts the local concentration of SNAC around the dissolving tablet reduces absorption. The MHRA approved Wegovy tablets as the first oral GLP-1 medicine licensed in the UK for weight management on 11 June 2026. Details on Wegovy's licensed use and eligibility explain what this means for people exploring treatment options.

Bioavailability of oral semaglutide remains lower than the injected form, which is why the maintenance tablet dose (25mg) is much higher in numerical terms than the injection's 2.4mg weekly dose, a comparison that surprises most people when they first see it. The two formulations are not interchangeable without clinical input, and if you want to understand the dose progression in more detail, our page on semaglutide 1mg covers the first stage of the injectable titration schedule. Prescription cost context for Wegovy is covered on our treatment options page.

What does the synthesis process mean for supply and quality?

Peptide synthesis at commercial scale is genuinely difficult. SPPS requires specialised equipment, pharmaceutical-grade raw amino acids, and rigorous purification. That complexity is part of why GLP-1 medicines cost what they do, and why shortages occurred globally when demand outpaced production capacity.

It also explains why counterfeit pens are dangerous in a specific way. Faking the packaging of a licensed medicine is one thing. Reproducing the chemistry of a correctly synthesised, purified and dosed peptide without a pharmaceutical-grade manufacturing process is quite another. The MHRA has warned repeatedly that fake pens seized in the UK have contained incorrect or contaminated substances, and our guides on semaglutide 2mg and semaglutide 3mg explain what a properly licensed dose at each of those stages should look like. Anyone considering buying these medicines should use a pharmacy they can verify on the GPhC register before handing over any details.

If you are looking at how to start treatment through a regulated UK route, our clinical team (including our lead prescriber) reviews every consultation personally. Questions about the process are answered on our FAQs page.

When you are ready to explore whether semaglutide-based treatment is right for you, our page on semaglutide 5mg explains what reaching that maintenance dose involves, and you can start your free consultation with a GPhC-registered prescriber who will review your case the same day.